Menu
 
Research menu
Jump to menu

Publications:  Dr John Riches

Aries JA, Davies JK, Auer RL, Hallam SL, Montoto S, Smith M, Sevillano B, Foggo V et al.(2020). Clinical Outcome of Coronavirus Disease 2019 in Haemato-oncology Patients. British Journal of Haematology
10.1111/bjh.16852
Riches JC, Gribben JG(2016). Mechanistic and clinical aspects of lenalidomide treatment for chronic lymphocytic leukemia. Current Cancer Drug Targets vol. 16,
10.2174/1568009616666160408145741
McClanahan F, Riches JC, Miller S, Day WP, Kotsiou E, Neuberg D, Croce CM, Capasso M et al.(2015). Mechanisms of PD-L1/PD-1 mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eμ-TCL1 CLL mouse model. Blood vol. 126, (2) 212-221.
10.1182/blood-2015-02-626754
McClanahan F, Riches JC, Miller S, Ghazaly E, Day W, Capasso M, Gribben J(2014). PD-1/PD-L1 mediated T-cell dysfunction in CLL is not absolute and can be at least partially reversed in vivo by the immune-modulatory drug lenalidomide. ONCOLOGY RESEARCH AND TREATMENT vol. 37, 236-236.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/6568
Riches JC, Gribben JG(2014). Immunomodulation and immune reconstitution in chronic lymphocytic leukemia. Semin Hematol vol. 51, (3) 228-234.
10.1053/j.seminhematol.2014.05.006
Riches JC, O'Donovan CJ, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS, Werner L, Croce CM et al.(2014). Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. BLOOD vol. 123, (26) 4101-4110.
10.1182/blood-2014-01-552307
Riches JC, O'Donovan CJ, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS, Werner L, Croce CM et al. (2014). Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. Blood. vol. 123, 4101-4110.
10.1182/blood-2014-01-552307
Riches JC, Gribben JG(2014). Hanging tough: CMV-specific CD8+ T cells in CLL. Blood vol. 123, (5) 608-609.
10.1182/blood-2013-12-540922
Riches JC, Gribben JG(2013). Advances in chimeric antigen receptor immunotherapy for chronic lymphocytic leukemia. Discov Med vol. 16, (90) 295-302.
Chen S-S, Herndon TM, Emson C, Riches JC, McClanahan F, Tong T, Yan X-J, Patten PEM et al. (2013). Intraclonal Complexity Of CLL Fractions In Cell Proliferation Rates, Gene Expression Signatures, and Responses To Autologous T-Cell Help In Peripheral blood and Secondary Lymphoid Tissues. BLOOD. vol. 122,
10.1182/blood.V122.21.115.115
Ene-Obong A, Clear AJ, Watt J, Wang J, Fatah R, Riches JC, Marshall JF, Chin-Aleong J et al.(2013). Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology vol. 145, (5) 1121-1132.
10.1053/j.gastro.2013.07.025
Riches JC, Gribben JG(2013). Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications. Hematol Oncol Clin North Am vol. 27, (2) 207-235.
10.1016/j.hoc.2013.01.003
Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, Ramsay AG, Gribben JG(2013). T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood vol. 121, (9) 1612-1621.
10.1182/blood-2012-09-457531
Gribben JG, Riches JC(2013). Immunotherapeutic strategies including transplantation: eradication of disease. Hematology Am Soc Hematol Educ Program vol. 2013, 151-157.
10.1182/asheducation-2013.1.151
McClanahan F, Ghirelli C, Greaves P, Riches JC, Coutinho R, Ramsay AG, Gribben JG (2012). Inhibitory Ligands CD200, CD270, CD274 and CD276 Are Expressed On E mu-TCL1 Transgenic Mouse Splenocytes and Are of Potential Relevance to Impaired T-Cell Function in Vivo. BLOOD. vol. 120,
10.1182/blood.V120.21.313.313
Riches JC, Gribben JG(2012). Less expensive CARs?. Cytotherapy vol. 14, (7) 773-774.
10.3109/14653249.2012.698119
Riches JC, Ramsay AG, Gribben JG(2012). Immune reconstitution in chronic lymphocytic leukemia. Curr Hematol Malig Rep vol. 7, (1) 13-20.
10.1007/s11899-011-0106-x
Riches JC, Ramsay AG, Gribben JG(2012). Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy. Curr Pharm Des vol. 18, (23) 3389-3398.
10.2174/138161212801227023
Riches JC, Sangaralingam A, Kiaii S, Chaplin T, Cekdemir D, Iqbal S, Ramsay AG, Gribben JG (2011). Impact of Lenalidomide on Gene Expression Profiles of Malignant and Immune Cells in Patients with Chronic Lymphocytic Leukemia. BLOOD. vol. 118, 446-446.
Riches JC, Ramsay AG, Gribben JG(2011). Chronic lymphocytic leukemia: an update on biology and treatment. Curr Oncol Rep vol. 13, (5) 379-385.
10.1007/s11912-011-0188-6
Riches JC, Davies J, Iqbal S, Fatah R, Agrawal S, Ramsay AG, Gribben JG (2011). T-cells from Patients With CLL Exhibit Phenotypic and Transcription Factor Profiles Of Exhaustion Independent of CMV Serostatus. Blood. vol. 118, 1780-1783.
Riches JC, Ramsay AG, Gribben JG(2010). T-cell function in chronic lymphocytic leukaemia. Semin Cancer Biol vol. 20, (6) 431-438.
10.1016/j.semcancer.2010.09.006
Riches JC, Gribben JG(2009). Interesting times in the diagnosis and treatment of CLL. Oncology (Williston Park) vol. 23, (12) 1043-1046.
Return to top